A cost-utility analysis of dabigatran, enoxaparin, and usual care for venous thromboprophylaxis after hip or knee replacement surgery in Thailand
Crossref DOI link: https://doi.org/10.1007/s11239-016-1433-5
Published Online: 2016-10-04
Published Print: 2017-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kotirum, Surachai
Chongmelaxme, Bunchai
Chaiyakunapruk, Nathorn
Funding for this research was provided by:
Boehringer Ingelheim (Thai) Ltd.
License valid from 2016-10-04